Toll Free: 1-888-928-9744

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 63 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2016', provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections
- The report reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Resistant Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects
- The report assesses Resistant Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Resistant Pseudomonas aeruginosa Infections Overview 7 Therapeutics Development 8 Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Overview 8 Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis 9 Resistant Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 10 Resistant Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 11 Resistant Pseudomonas aeruginosa Infections - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Resistant Pseudomonas aeruginosa Infections - Products under Development by Companies 14 Resistant Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 15 Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 16 Achaogen Inc. 16 AstraZeneca Plc 17 Biolytics Pharma 18 CSA Biotechnologies LLC 19 LegoChem Biosciences, Inc 20 Melinta Therapeutics, Inc 21 Phico Therapeutics Limited 22 Phylogica Limited 23 Shionogi & Co., Ltd. 24 Zambon Company S.p.A. 25 Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 ACHN-975 Prodrug - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CSA-13 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 G-10 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 LCB-010200 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 LCB-100200 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 PT-3.33 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 RXP-763 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 RXP-766 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 RXP-770 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 RXP-792 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 RXP-793 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 RXP-808 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 RXP-873 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 S-649266 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ZP-046 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Resistant Pseudomonas aeruginosa Infections - Recent Pipeline Updates 58 Resistant Pseudomonas aeruginosa Infections - Dormant Projects 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H1 2016 8 Number of Products under Development for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Resistant Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc., H1 2016 16 Resistant Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H1 2016 17 Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H1 2016 18 Resistant Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H1 2016 19 Resistant Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 20 Resistant Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 21 Resistant Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Limited, H1 2016 22 Resistant Pseudomonas aeruginosa Infections - Pipeline by Phylogica Limited, H1 2016 23 Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H1 2016 24 Resistant Pseudomonas aeruginosa Infections - Pipeline by Zambon Company S.p.A., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Resistant Pseudomonas aeruginosa Infections Therapeutics - Recent Pipeline Updates, H1 2016 58 Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H1 2016 61


List of Figures
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H1 2016 8 Number of Products under Development for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Targets, H1 2016 27 Number of Products by Stage and Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 33 Number of Products by Stage and Molecule Types, H1 2016 33

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify